Match!

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening

Published on Oct 1, 2019in International Journal of Urology2.107
· DOI :10.1111/iju.14039
Kazuto Ito27
Estimated H-index: 27
(Gunma University),
Ryo Oki1
Estimated H-index: 1
+ 5 AuthorsIsao Kurosawa1
Estimated H-index: 1
Abstract
  • References (90)
  • Citations (1)
📖 Papers frequently viewed together
2005
1 Author (Robert S. Tan)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References90
Newest
#1Pieter De Visschere (Ghent University Hospital)H-Index: 12
#2Chloë Standaert (Ghent University Hospital)H-Index: 2
Last. Stefano Fanti (UNIBO: University of Bologna)H-Index: 57
view all 11 authors...
Abstract Context In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic. With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low. Objective To systematically review the literature on the role of the existing imaging techn...
10 CitationsSource
#1Ryo OkiH-Index: 1
#2Kazuto ItoH-Index: 27
Last. KazuhirosuzukiH-Index: 40
view all 11 authors...
1 CitationsSource
#1Dragan Ilic (Monash University)H-Index: 27
#2Mia Djulbegovic (Yale University)H-Index: 6
Last. Philipp Dahm (UMN: University of Minnesota)H-Index: 41
view all 8 authors...
Abstract Objective To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer. Design Systematic review and meta-analysis. Data sources Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018. Eligibility criteria for selecting studies Randomised controlled trials comparing PSA screening with ...
22 CitationsSource
#1Per-Olof Lundgren (KI: Karolinska Institutet)H-Index: 1
#2Anders Kjellman (KI: Karolinska Institutet)H-Index: 6
Last. Ove Gustafsson (KI: Karolinska Institutet)H-Index: 19
view all 4 authors...
Purpose: We evaluated the long-term effect of screening for prostate cancer.Materials and Methods: In 1988 we randomly selected 2,400 men from a background population of 27,464 men. The 2,400 men were invited to undergo screening, of whom 1,779 (74%) accepted and were examined with digital rectal examination, ultrasound and prostate specific antigen measurement. Biopsy was performed if there were suspicious findings on ultrasound or digital rectal examination, or prostate specific antigen was gr...
5 CitationsSource
#1Michael S. Hofman (University of Melbourne)H-Index: 27
#2John Violet (Peter MacCallum Cancer Centre)H-Index: 7
Last. Shahneen Sandhu (University of Melbourne)H-Index: 23
view all 15 authors...
Summary Background Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [ 177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of...
87 CitationsSource
#1Veeru Kasivisvanathan (London North West Healthcare NHS Trust)H-Index: 6
#2Antti Rannikko (London North West Healthcare NHS Trust)H-Index: 24
Last. Caroline M. Moore (London North West Healthcare NHS Trust)H-Index: 26
view all 41 authors...
Abstract Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to under...
352 CitationsSource
#1David C. Grossman (KP: Kaiser Permanente)H-Index: 19
#2Susan J. Curry (UI: University of Iowa)H-Index: 27
Last. Chien Wen Tseng (UH: University of Hawaii)H-Index: 25
view all 18 authors...
Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men. Objective To ...
184 CitationsSource
#1Richard M. Martin (UoB: University of Bristol)H-Index: 102
#2Jenny L Donovan (NIHR: National Institute for Health Research)H-Index: 82
Last. Freddie C. Hamdy (University of Oxford)H-Index: 71
view all 26 authors...
Importance Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer–specific mortality. Design, Setting, and Participants The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years ...
63 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 47
#2Kimberly D. Miller Mph (ACS: American Cancer Society)H-Index: 2
Last. Ahmedin Jemal Dvm (ACS: American Cancer Society)H-Index: 4
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
3,124 CitationsSource
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
4,299 CitationsSource
Cited By1
Newest
#1Masaki MomotaH-Index: 3
#2Shingo Hatakeyama (Hirosaki University)H-Index: 23
Last. Atsushi ImaiH-Index: 12
view all 14 authors...
OBJECTIVES To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer. METHODS Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot-assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone-naive prostate cancer or castration-resistant prostate cancer. The prim...
1 CitationsSource
Abstract A rapid aptasensor capable of early diagnosing prostate cancer was developed using a dual aptamer, which is composed of a prostate specific antigen (PSA) aptamer and hemin aptamer connected by a linker composed of 5 adenines. The dual aptamers immobilized on the surface of paramagnetic beads were able to competitively bind with PSA or hemin in human serum for 20 min at room temperature. After the incubation, the dual aptamers were separated from human serum using a magnetic separator. A...
Source
#1Masaki Momota (Hirosaki University)H-Index: 3
#2Shingo Hatakeyama (Hirosaki University)H-Index: 23
Last. Hayato Yamamoto (Hirosaki University)H-Index: 14
view all 13 authors...
Source
#1Teppei Matsumoto (Hirosaki University)H-Index: 5
#2Shingo Hatakeyama (Hirosaki University)H-Index: 23
Last. Chikara Ohyama (Hirosaki University)H-Index: 31
view all 11 authors...
We investigated the diagnostic and prognostic potential of serum N-glycan profiling for castration-resistant prostate cancer (CRPC). We retrospectively investigated serum N-glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N-Glycan profiling was compared between th...
Source